C4X Discovery Hldg (C4XD) Stock Discussion | Share discussion

C4X Discovery Hldg

C4X Discovery Holdings plc, through its subsidiaries, operates as a biotechnology company in the United Kingdom.

Industry: Pharmaceuticals & Biotechnology

Ticker	Exchange	ISIN
$C4XD	LSE AIM	GB00BQQ2RV18

Recent news

Carnival Net Income dropped on 442% and Revenue dropped on 73.1%

Unisys Corp reports 4,465% Net Income growth in 2020 while 31.3% Revenue decline

Northamber Net Income surged on 1,523%

International Bus Mach Corp reports 40.7% Net Income decline in 2020 and 3.2 pp EBITDA Margin decline from 20.7% to 17.5%

Blue Prism Group plc revenue surged on 40% and EBITDA Margin surged on 28.9 pp from -78.3% to -49.4%

Tui Ag EBITDA dropped on 220% and Revenue dropped on 58.0%

Zytronic Net Income dropped on 111% and EBITDA Margin dropped on 15.0 pp from 20.6% to 5.6%

Image Scan Hldgs revenue surged on 47.3% and EBITDA Margin surged on 21.0 pp from -16.0% to 5.0%

Oxford Metrics Net Income dropped on 61.6% and Revenue dropped on 14.3%

I-Nexus Global Plc revenue dropped on 14.3%

Twit about C4XD stock

Share your investment idea or question on C4X Discovery Hldg stock:

Latest twits on C4X Discovery Hldg (C4XD)

No twits yet. Be the first to post!

Have a question about C4XD? Ask and other investors will be eager to help you.

Have an idea about C4XD? Share it with other investors.

C4X Discovery Hldg news

21 Nov 2018 C4X Discovery Hldg revenue returned to growth in FY2018: increased 4,840% vs. 48.7% decline a year earliner

C4X Discovery Hldg stock price chart

C4X Discovery Hldg financials

mln. £	FY2013	FY2014	FY2015

Revenue	0.736	0.619	0.312
EBITDA	-0.573	-1.207	0.000
Net income	-0.481	-1.118	0.000
CAPEX	0.014	0.007	0.000
Debt	2.144	2.263	0.000
Cash	1.514	0.673	0.000

C4X Discovery Hldg news

21 Nov 2018 C4X Discovery Hldg revenue returned to growth in FY2018: increased 4,840% vs. 48.7% decline a year earliner

About C4X Discovery Hldg

C4X Discovery Holdings plc, through its subsidiaries, operates as a biotechnology company in the United Kingdom. It develops technologies to enhance the drug discovery process for novel small molecule therapies. The company